Phenazopyridine
Azo (phenazopyridine) is a small molecule pharmaceutical. Phenazopyridine was first approved as Azo gantanol on 1987-09-10. It is used to treat pain and urological manifestations in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phenazopyridine hydrochloride
+
Sulfamethoxazole
Phenazopyridine hydrochloride
+
Sulfamethoxazole
+
Trimethoprim
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE | Able Laboratories | N-021105 DISCN | 2001-06-26 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pain | EFO_0003843 | D010146 | R52 |
| urological manifestations | — | D020924 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | 1 | — | 2 |
| Urinary retention | D016055 | HP_0000016 | R33 | — | — | 1 | 1 | — | 2 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | 1 | — | 1 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | — | — | 1 | — | 1 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dysuria | D053159 | EFO_0003901 | R30 | — | — | 2 | — | — | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 2 | — | — | 2 |
| Postoperative pain | D010149 | — | G89.18 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | — | — | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystoscopy | D003558 | — | — | — | — | — | — | 2 | 2 |
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | — | — | 1 | 1 |
| Stress urinary incontinence | D014550 | HP_0010992 | — | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Nephrolithiasis | D053040 | — | N20.0 | — | — | — | — | 1 | 1 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | — | — | 1 | 1 |
| Urolithiasis | D052878 | — | N20-N23 | — | — | — | — | 1 | 1 |
| Ureteral calculi | D014514 | — | — | — | — | — | — | 1 | 1 |
| Ureteral diseases | D014515 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Phenazopyridine |
| INN | phenazopyridine |
| Description | Phenazopyridine is a diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. It has a role as a local anaesthetic, a non-narcotic analgesic, a carcinogenic agent and an anticoronaviral agent. It is a diaminopyridine and a monoazo compound. It is a conjugate base of a phenazopyridine(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(/N=N/c2ccccc2)c(N)n1 |
Identifiers
| PDB | — |
| CAS-ID | 94-78-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1242 |
| ChEBI ID | — |
| PubChem CID | 4756 |
| DrugBank | DB01438 |
| UNII ID | K2J09EMJ52 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Phenazopyridine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Phenazopyridine
+
Sulfisoxazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 698 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
510 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use